Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
25 sept. 2019 02h15 HE
|
Hutchison China MediTech Limited
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with...
Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting
18 sept. 2019 02h15 HE
|
Hutchison China MediTech Limited
LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib...
Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
03 sept. 2019 02h46 HE
|
Hutchison China MediTech Limited
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside...
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma
03 sept. 2019 02h25 HE
|
Hutchison China MediTech Limited
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and...
Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China
23 août 2019 02h15 HE
|
Hutchison China MediTech Limited
LONDON, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”)...
Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs
30 juil. 2019 04h43 HE
|
Hutchison China MediTech Limited
LONDON, July 30, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and...
Chi-Med to Announce 2019 Half-Year Financial Results
03 juil. 2019 02h00 HE
|
Hutchison China MediTech Limited
LONDON, July 03, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday,...
Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares
28 juin 2019 05h33 HE
|
Hutchison China MediTech Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION LONDON,...
Chi-Med Announces Secondary Offering of American Depositary Shares
27 juin 2019 17h37 HE
|
Hutchison China MediTech Limited
LONDON, June 27, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that Hutchison Healthcare Holdings Limited (“HHHL”), the largest shareholder of...
Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early
14 juin 2019 04h00 HE
|
Hutchison China MediTech Limited
LONDON, June 14, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III...